Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pfizer brands
Esreboxetine
Другие языки:

    Esreboxetine

    Подписчиков: 0, рейтинг: 0
    Esreboxetine
    Esreboxetine.svg
    Clinical data
    Other names AXS-14; PNU-165442G
    Routes of
    administration    		 Oral
    ATC code
    • None
    Legal status
    Legal status
    • In general: uncontrolled
    Identifiers
    • (2S)-2-[(S)-(2-ethoxyphenoxy)phenyl
      methyl]morpholine
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    KEGG
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C19H23NO3
    Molar mass 313.397 g·mol−1
    3D model (JSmol)
    • CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
    • InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1 ☒N
    • Key:CBQGYUDMJHNJBX-OALUTQOASA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.

    However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.


    Новое сообщение